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Abstract
Objective—Autosomal dominant cortical myoclonus and epilepsy (ADCME) is characterized by
distal, fairly rhythmic myoclonus and epilepsy with variable severity. We have previously mapped
the disease locus on chromosome 2p11.1-q12.2 by genome-wide linkage analysis. Additional
pedigrees affected by similar forms of epilepsy have been associated to chromosome 8q, 5p and
3q, but none of the causing genes has been identified. We aim at identifying the mutant gene
responsible for this epileptic form.
Methods—Genes included in the ADCME critical region were prioritized and directly
sequenced. Co-immunoprecipitation, immunofluorescence and electrophysiology approaches on
transfected human cells have been utilized for testing the functional significance of the identified
mutation.
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Results—Here we show that mutation in the α2-adrenergic receptor subtype B (α2B-AR)
associates to ADCME by identifying a novel in-frame insertion/deletion in two Italian families.
The mutation alters several conserved residues of the third intracellular (3i) loop, neither
hampering the α2B-AR plasma membrane localization nor the arrestin-mediated internalization
capacity, but altering the binding with the scaffolding protein spinophilin upon neurotransmitter
activation. Spinophilin, in turn, regulates interaction of GPCRs with Regulators of G proteins
Signaling proteins. Accordingly, the mutant α2B-AR increases the epinephrine-stimulated calcium
signaling.
Interpretation—The identified mutation is responsible for ADCME, as the loss of α2B-AR/
spinophilin interaction causes a gain of function effect. This work implicates for the first time the
α-adrenergic system in human epilepsy and opens new ways for understanding the molecular
pathway of epileptogenesis, widening the spectrum of possible therapeutic targets.
Introduction
Autosomal dominant cortical myoclonus and epilepsy (ADCME, OMIM 607876; also
Cortical Myoclonic Tremor With Epilepsy, Familial, 2; FCMTE2) and benign adult
myoclonic epilepsy (BAFME/FAME, OMIM 601068 ) are syndromes with high penetrance,
characterized by rhythmic myoclonic jerks of cortical origin and focal or generalized tonic-
clonic seizures, with non-progressive or slowly progressive course. Initially, these
conditions were classified as separate entities, although they might exhibit considerable
clinical overlap 1. Clinical and neurophysiological features suggest a high propensity for
intra-hemispheric and inter-hemispheric cortical spread of cortical myoclonic activity,
indicating widespread cortical hyperexcitability with defective inhibitory cortical
mechanisms 2. The diseases-associated loci have been mapped to chromosomes 8q23.1-
q24.11 and 2p11.1-q12.2 in Japanese and Italian families, respectively 2-4. Additional loci
have recently been identified on chromosomes 5p15.31-p15 5 and 3q26.32-3q28 6,
supporting genetic heterogeneity among pedigrees. Several candidates have been proposed
but, to date, causative genes for this group of disorders have not yet been identified.
Here we report the association of the α2B-adrenergic receptor with ADCME in two
unrelated families. The adrenergic system has been proposed since the late ‘80s to be
implicated in epileptogenesis, as impaired activation of α2 adrenergic receptors might
contribute to epileptogenesis in the kindling model 7, 8. The α2 adrenergic receptors (α2-
ARs) belong to the G protein coupled receptors (GPCRs) family that binds the endogenous
ligands epinephrine and norepinephrine. These seven transmembrane-spanning receptors
regulate their effector systems via coupling to heterotrimeric G-proteins that mediate the
physiological effects, such as sympathetic outflow and cardiovascular function 9. The
sympathetic nervous system activity is negatively regulated by α2-adrenoreceptors that act
as autoreceptors, suppressing release of catecholamines. Their inhibitory activities are
mediated by inhibition of adenylyl cyclase and voltage-gated Ca2+ currents and activation of
receptor-operated K+ currents 10. The α2-ARs, like most GPCRs, are substrate of G protein-
coupled kinases (GRKs): GRK2 binds and phosphorylates the agonist-activated receptor,
converting it into a target for high affinity binding of arrestin to regulate the receptor
signaling cascades. Bound arrestin shields the cytoplasmic surface of the receptor,
precluding G protein binding and activation 11. Desensitized receptor-arrestin complexes are
endocytosed and the receptors are dissociated, dephosphorylated and recycled to the cell
surface, re-sensitizing the cell for another round of signaling. Another important mode of
regulation is by the effector spinophilin, which regulates multiple aspects of α2-AR
trafficking and signaling by antagonizing the interaction with GRK2 and subsequent arrestin
binding12. Thence, the interaction of spinophilin with the α2-AR decreases arrestin-
dependent internalization of the receptor, thus stabilizing it at the cell surface, and slows the
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rate of both activation and resensitization of receptor-mediated signaling. 12. In addition,
spinophilin mediates interaction of the α2B-AR with Regulators of G proteins Signaling
(RGS) proteins to reduce signaling intensity 13 .
To date, three distinct α2-adrenergic receptor (α2-AR) subtypes (α2A, α2B, α2C) have been
described in humans 14, which are encoded by three intronless genes localized on
chromosomes 10, 2 and 4. The α2-ARs are distributed throughout the central nervous system
(CNS) with no extensive overlap, indicating a probable role in discrete neuronal functions
by coordinating independent neural signaling pathways. Although the three receptors have
similar pharmacological properties, they show subtype-specific differences in susceptibility
to regulatory phosphorylation and desensitization, as well as intracellular trafficking 15. A
key role in the signaling pathway is played by the third intracellular (3i) loop of the α2-AR,
which includes the sites for GRK phosphorylation, Gi activation and binding of spinophilin
and arrestin 16. Interestingly, the α2B-AR mutation reported here involves consistent
changes of this crucial controller domain.
Patients and Methods
Patients’ evaluation
All affected members underwent video-polygraphic study, jerk-locked back averaging
(JLA), somatosensory evoked potentials (SEPs) and long latency reflex I (LLRI). Detailed
methods have been described elsewhere 217, SEPs were judged as giant when the
components N20-P25 and P25-N33 were larger than 8·6μV and 8·4μV. Neuropsychological
evaluation included Wechsler Adult Intelligence Scale Revised.
Mutation detection
Mutation analysis of candidate genes was performed by amplifying coding sequences
scanning by D-HPLC (Wave, Transgenomic) and direct sequencing. Screening of conrols
for the ADCME mutation was performed by ARMS-PCR assay amplifying both the wild-
type and the mutant alleles, together with a control fragment, in a single-tube PCR. The
region flanking the mutation was amplified by two outer primers, producing a nonallele-
specific control amplicon. Two allele-specific inner primers were designed in opposite
orientation and used in combination with the common outer primers to simultaneously
amplify both the wild-type and the mutant amplicons. The allele-specific primers specificity
was conferred by the match of the 3’ nucleotides with either the wild-type or the mutant
allele. The tetra ARMS-PCR produced two allele-specific amplicons with different lengths
(316bp for wild-type; 205bp for mutant) and one control amplicon that was always present
(486bp). Primers sequences and PCR conditions are available upon request.
Targeted Capture and DNA Sequencing
gDNA were nebulized and the libraries prepared using a GS FLX Titanium Rapid Library
Preparation Kit (Roche, Milan, Italy). In order to multiplex the two samples in a single
sequencing run, two different MID identifiers have been used. The libraries were pooled and
hybridized on a Titanium Optimized Sequence Capture 385K Array (Roche-Nimblegene,
Madison, WI-USA). The array was designed to capture the coding and the UTRs regions of
the UCSC genes localized in the extended linkage region (hg18/NCBI36;
chr2:85,140,498-112,715,205). Additional 20 bp of flanking intronic sequence were added
to each exon. Captured libraries were subjected to emulsion PCR, and DNA-carrying beads
were enriched and used as template for sequencing according to manufacturer's protocol. GS
FLX sequence reads were aligned to the NCBI36/hg18 reference genome using the GS
Reference Mapper v2.5.3. Variants were filtered and annotated using the ANNOVAR tool.
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Sequence Alignments
We used ClustalW2 to compare α2B-AR (NP_000673.2) with orthologs of P. troglodytes
(XP_003309176.1), C. apella (CAJ19284.1), P. pithecia (CAJ19290.1), H. lar
(CAJ19281.1), M. mulatta (XP_001082230.1), C. solatus (CAJ19319.1), P. abelii
(XP_002811692.1), T. indicus (AEP17928.1) and C. porcellus (XP_003471576.1).
Molecular modeling
The three-dimensional structure of wild type and mutant α2B-AR were produced using
Swiss-Model server (http://swissmodel.expasy.org/)1819, which performs sequence
alignment and putative template protein selection for the generation of the 3d model of the
query protein
Plasmid preparation
Full length wild type and mutant α2B-AR was amplified from genomic DNA with primers
encoding the KpnI-EcoRI sites and the 5’HA tag and subcloned into pcDNA3.1(+)
(Invitrogen, Carlsbad, CA, USA). Myc tagged spinophilin was prepared as described
before 20. FLAG-tagged arrestin3 were kindly provided by Dr Robert J. Lefkowitz (Duke
University, Durham, NC, USA).
Immunofluorescence microscopy
HeLa cells were seeded at 104/well in 12-well plates on glass coverslips and cultured in
Dulbecco's modified Eagle's medium (DMEM) supplemented with 5% fetal bovine serum
(FBS). Cells were transiently transfected with plasmid encoding wild type or mutant HA-
tagged α2B-AR alone or in combination with FLAG-tagged arrestin3 (0·45μg and 0 ·15μg
respectively). After 36 hours, to visualize cell surface receptors, cells were washed and
incubated with DMEM supplemented with 0·1% BSA, 25mM HEPES and containing mouse
anti-HA antibody (6μg/ml, Covance) for 1 hour at 4°C. After washing, cells were treated
with 100 mM epinephrine for 10 minutes at 37°C, washed, fixed with 4%
paraformaldehyde, permeabilized with 0.1% Triton X-100 and incubated with Alexa-488
conjugated secondary antibody. Nuclei were stained by 4',6-diamidino-2-phenylindole
(DAPI). Images were captured by using a ZEISS Imager A2 microscope and obtained under
a 40x Plan-Apochromat M27 objective (Zeiss).
Co-immunoisolation of Spinophilin with the WT and mutant α2B-AR
CosM6 cells were transfected with a plasmid encoding myc-tagged spinophilin (pCMV4-
Myc-Sp) together with a plasmid encoding HA-tagged WT or mutant α2BAR (pcDNA3.1-
HA-α2BAR or pcDNA3.1-HA-α2BAR-mut) using Lipofectamine 2000 (Invitrogen). 24 h
post-transfection, cells were serum starved overnight, and then treated with 100 μM
epinephrine (plus 1μM prazosin to block α1AR and 1μM propranolol to block βAR) or
vehicle for 5 or 10 min. After stimulation, cells were lysed in buffer containing 20 mM
HEPES (pH 7.4), 0.5% NP-40, 10% glycerol, 2 mM EDTA, 5 mM sodium fluoride and
protease inhibitor cocktail (100 μM PMSF, 10 μg/ml leupeptin, 5 μg/ml aprotinin, 1 μg/ml
soybean trypsin inhibitor and 1μM pepstain), and centrifuged at 13,000 rpm for 30 min at 4
°C. The supernatant was collected as total cell lysates and measured for protein
concentration. The equal amount of total proteins was used for co-immunoprecipation assay.
Cell lysates were precleared with 35μl of protein G beads slurry for 45 min at 4 °C, and then
incubated with HA.11 antibody (Covance, 1:100) overnight at 4 °C. The HA
immunocomplex was pull downed by adding 35μl of protein G beads slurry (pre-
equilibrated with 0.25% BSA and washed) into the cell lysates and rotating for 2 hours at 4
°C. Protein G beads were washed 3 times with lysis buffer and bound proteins were
extracted with Laemmli sample buffer.
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Current measurement in Xenopus laevis oocytes
The SPL cDNA was cloned in pCMV-myc vector (Clontech, Palo Alto, CA). For the
synthesis of cRNA, the desired cDNAs constructs were linearized and the T7 promoter
upstream of the sequence of interest were used for cRNA synthesis in vitro using SP6 RNA
polymerase (Ambion, Life Technologies, Paisley, UK). X. laevis oocytes were prepared as
previously described 20. Briefly, oocytes in stage V–VI were injected with 2–10 ng cRNA
encoding wild type or mutant α2B-AR alone or in combination with spinophilin and
incubated at 18°C in 96 mM NaCl, 1 mM MgCl2, 1 mM CaCl2 and 5 mM HEPES (pH 7·6)
buffer. Current measurement was accomplished 48–96 h post-injection with the two-
electrode voltage-clamp procedure. When performing dose response, the effect of each α2B-
AR and spinophilin concentration on Ca2+ signaling was measured after the same incubation
time post-injection. To measure the Ca2+-activated Cl– current, membrane potential was
held at –60 mV for continuous recording. To acquire epinephrine dose–response
relationships, membrane potential was stepped from –60 mV to + 50 mV for 200 ms at 0.2
Hz. The results are shown as means ± s.e.m. of the peak current normalized on wild type.We
used 2 oocyte preparations and did the 6 experiments over 4 days, starting 96 hrs after
cRNA injection. In each experiment we performed the dose response in all conditions in the
same day (wild type, mutant, wild type +SPL, mutant+SPL). The pick current at each
concentration was used to calculate the response and for p we used all 6 experiments. The
maximum current was similar for all conditions. The current was measured at a holding
potential of −30 mV and the traces show the Ca2+ activated Cl− current.
Results
Identification of α2-adrenergic receptor subtype B mutation in ADCME patients
We have previously mapped the ADCME locus on chromosome 2p1.1-q1.2 in a five-
generation family from Tuscany with autosomal dominant pattern of inheritance 2 (Fig. 1;
Family A). Among the several genes included in the critical region, we prioritized as
possible candidates SIAT9, demonstrated to be involved in the autosomal recessive Amish
infantile epilepsy syndrome (AIES) 21; KCNIP3, coding for a calcium binding protein that
regulates voltage-gated potassium current and hence neuron excitability 22; REEP1,
involved in the spastic paraplegia autosomal dominant type 31 23, VAMP5 and VAMP8,
required for vesicle fusion and neurotransmitter release and the neuronal transcription factor
NPAS2. Sequence analysis of the coding regions of these genes gave negative result.
Finally, we identified a novel in-frame insertion/deletion in the α2-adrenergic receptor
subtype B gene (α2B-AR; ADRA2B), which substitutes five amino acids, HGGAL, with four
new residues, QFGR, (indel; c.675_686delTGGTGGGGCTTTinsGTTTGGCAG;
p.H225_L229delinsQ225_F_G_R228) (Fig. 2A).
This indel mutation completely co-segregates with the disease phenotype and is absent in
575 unrelated controls from Tuscany (data not shown), in dbSNP (http://
www.ncbi.nlm.nih.gov/projects/SNP/), in the Exome Variant Server (NHLBI GO Exome
Sequencing Project, Seattle, WA; http://evs.gs.washington.edu/EVS/), and in the 1000
Genomes Project (http://www.1000genomes.org/), thus totaling 16080 human
chromosomes. It is worth noting that a frequent ADRA2B polymorphism resulting in a
different number of the encoded glutamic acid residues in the monotonous stretch
p.E297_E309 is known to represent a risk factors for cardiovascular and metabolic
diseases 2425 and to disregulate agonist-promoted receptor desensitization 26. However, the
identified mutation is syntenic to the more common variant showing 12 consecutive
glutamic acid residues, variant that is not associated to the above mentioned effects. Other
indels of the ADRA2B gene found in the control population are reported in a Supplementary
Table 1.
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In a second ADCME family from Tuscany (Fig. 1; Family B) we detected the same indel of
the ADRA2B gene. Although no kinship between the two families was discovered by
anamnestic analysis of members of the two pedigrees, a common ancestor is to be expected
as they share the same disease haplotype spanning the entire critical region on chromosome
2 (data not shown). BAFME pedigrees originating from Southern Italy have been shown to
map in the ADCME locus 27, 28. However, we failed to detect any ADRA2B mutations in
these pedigrees by direct sequence analysis and excluded potential large insertion and
deletions by southern blot (data not shown).
In order to exclude other possible variations that could explain or contribute to the onset of
the ADCME phenotype, we extensively sequenced two affected members of Family A by
target capturing all the coding regions included in the ADCME critical region followed by
highly-redundant next generation sequencing. The ADRA2B mutation was confirmed as the
unique relevant chance (data not shown).
Clinical features of the ADCME families
The clinical features of family A have been previously described 2 and closely resemble
family B phenotype (clinical findings are summarized in Table 1). Briefly, family B is a
four-generation kindred including 5 affected members (4 living). All patients exhibited
postural hand and upper limbs myoclonus. Epilepsy occurred in all but one (IV:1)
individuals and was characterized by rare generalized tonic-clonic seizures, at times
precipitated by visual stimuli, occurring in all patients and by drug resistant focal motor or
complex partial seizures occurring in patients III: 2 and III:5. Individual III:2 exhibited
borderline cognitive level, while all remaining affected individuals had normal intelligence.
Cortical tremor was the presenting symptom in all affected individuals, appearing between
the ages of 18 to 50 years. Generalized or focal paroxysmal activity was identified in all
patients. Jerk-locked back averaged EEG, somatosensory evoked potentials, and long-loop
reflex, were consistent with the cortical reflex myoclonus.
We took into consideration a possible co-morbidity of epilepsy with cardiovascular diseases
as the ADRA2B gene is also expressed in the heart and vascular smooth muscles. A careful
anamnesis was performed on all ADCME patients giving negative evidence for
cardiovascular diseases; two of the oldest ADRA2B mutation carriers developed age-related
dementia.
Mutant α2B-adrenergic receptor internalization is unaffected
The indel localizes in the third intracellular (3i) loop, a crucial domain for receptor
localization and signal transduction, conserved in primates 16 (Fig 2B). The mutant amino
acid stretch Gln225_Phe_Gly_Arg228 is expected to result in different physical-chemical
properties of the domain in comparison to the wild type, due to the insertion of a very
hydrophobic and bulky residue (Phe226) and a positive charge (Arg228). Since no crystal
structure of the α2B-AR is yet available, we generated a three-dimensional configuration
model in order to investigate the impact of the mutation on the structure of the receptor by
using the dopamine D3 receptor as a template 29. As shown in Fig. 3, the mutant is predicted
to prominently alter the conformation of the specific region of the 3i loop. We therefore
tested if these changes can affect the α2B-AR subcellular distribution and its ability to
interact with other proteins.
Since the 3i loop has been demonstrated to be critical for intramembrane stability 30 we first
determined the wild type and mutant α2B-AR subcellular localization by
immunofluorescence. Both wild type and mutant α2B-AR show the typical plasma
membrane localization in the absence of agonist, indicating that the mutation does not affect
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the maturation of the protein in the ER-Golgi compartments and its delivery to the plasma
membrane (Fig. 4A and D). When cells were stimulated with epinephrine, little or no
redistribution of α2B-ARs was detected (Fig. 4B and E), while in the presence of arrestin-3,
wild type α2B-AR relocalizes to endosomes as expected 31 as well as the mutant receptor
(Fig. 4C and F). These results suggest that both wild type and mutant α2B-AR internalize in
an arrestin-3-dependent manner and that the arrestin-3 interaction with the 3i loop is not
precluded by the mutation that indeed is apart from the arrestin-3- α2B-AR interaction
domain .
Mutant α2B-adrenergic receptor alters spinophilin interaction
We studied the possible destabilizing effect of the mutant isoform on the interaction between
the α2B-AR and spinophilin, as the latter has been demonstrated to specifically bind the α2A-
AR 3i loop 32 . The interaction was initially investigated by GST-pull down; both wild type
and mutant α2B-AR were found to bind spinophilin, indicating that the mutant retains the
ability to bind spinophilin in vitro (data not shown).
We confirmed this interaction by co-immunoisolation assay. As shown in the Fig. 5A and B,
spinophilin was present in the immunocomplex with α2B-AR. Activation of the receptor by
epinephrine significantly enhanced the amount of spinophilin co-isolated with the α2B-AR,
thus indicating that spinophilin preferentially interacts with the agonist-activated α2B-AR, in
line with previous findings35. After 5-min treatment of epinephrine, spinophilin was co-
immunoisolated with comparable amount of wild type and mutant α2B-AR. However, the
amount of spinophilin co-isolated with the mutant α2B-AR dropped back to the basal level
after epinephrine treatment for 10 min, whereas the amount of spinophilin co-isolated with
the wild type α2B-AR remained elevated with the same treatment (Fig. 5C). These data
suggest that the mutant α2B-AR cannot form a stable complex with spinophilin, which
would result in lack of spinophilin regulation on responses mediated by this mutant α2B-AR.
Mutation in α2B-AR induces an alteration in the Ca2+ signaling
We therefore tested the effect of the α2B-AR mutation on epinephrine-activated Ca2+
signaling. Epinephrine stimulation activates a Gq-mediated Ca2+ signaling as revealed by
activation of the native oocytes Ca2+-activated Cl− current. Spinophilin attenuate the
signaling by recruiting RGS proteins to the receptors-G protein complex, which accelerates
the Gα-GTPase activity to terminate the signal 13. To test the effect of the mutation on the
role of spinophilin in Ca2+ signaling, Xenopus laevis oocytes were injected with cRNA
encoding wild type or mutant α2B-AR alone or in combination with spinophilin and Ca2+-
activated Cl− current was measured upon stimulation with increasing concentrations of
epinephrine. The dose-response measurement showed that spinophilin significantly
increased the EC50 for epinephrine (p<0.01; Fig.6), as previously demonstrated for α1B-
AR 13. The expression of the mutant α2B-AR exhibits per se a trend toward significant
reduction of the EC50 compared to wild type (p=0.055), but the presence of spinophilin does
not result in an increase in EC50 (α2B-AR + SPN versus α2B-AR mutant + SPN: p<0.001;
Fig.6). Therefore, we conclude that the mutant α2B-AR significantly increases the intensity
of Ca2+ signaling by the receptors.
Discussion
Although Mendelian inherited epilepsies represent a small share of epilepsy at large, the
study of mutant proteins has greatly improved our understanding of the disease mechanisms.
Genetic forms of epilepsy have been associated with mutations in the voltage-gated sodium,
potassium and calcium channels, in the neurotransmitter-gated ion channels, the nicotinic
acetylcholine receptor and the γ-aminobutyric acid receptor subtype A (GABAA), in
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transcription factors (ARX), in proteins involved in synaptic vesicle release, and in cerebral
cortex development and plasticity 33. Here we provide evidence that α2B-AR is directly
involved in human epilepsy such as ADCME. We did not detect any mutation in ADRA2B in
BAFME/FAME patients, suggesting the possibility of classifying ADCME and BAFME/
FAME as two distinct clinical entities. However, we cannot exclude the presence of
variations in gene regulatory regions or other non-coding genomic elements potentially
affecting gene function.
ADCME is characterized by familial occurrence of cortical reflex myoclonus manifested as
action-induced shivering movement of the hands and upper limb jerking variably associated
with focal and generalized tonic-clonic seizures of variable severity and, in a minority of
patients, with borderline or moderately impaired cognitive skills. Worsening of myoclonus
is often observed in advanced age 34 .
The indel of the α2B-AR does not affect the protein localization, but our model predicts a
change in folding of the 3i loop, the largest cytoplasmic domain that mediates agonist-
dependent binding and activation of heterotrimeric G proteins. Although the 3i loop exerts
the same function in all α2A, α2B, α2C -AR subtypes, it shows constitutive difference, as its
amino acid sequence is poorly conserved among subtypes, suggesting a possible subtype-
specific sensitivity to regulation. The α2B-AR 3i loop is bigger and contains a long stretch of
glutamic acids that counterbalances the diffuse positive charge of the domain, which is
instead predominant in the α2A-AR and α2C-AR 3i loops. This glutamic acid repeat is
polymorphic for the presence of long and short alleles with 12 or 9 residue repetitions35. The
less frequent shorter allele has been associated with undetectable agonist-induced down-
regulation of the receptor 36, though no association with epilepsy was reported so far.
However, the α2B-AR ADCME mutation reported here engages the most common longer
allele and, therefore, it was the isoform used for building both the control and ADCME
mutant transfection constructs.
The mutation does not impair the receptor internalization triggered by the binding with
arrestin-3, but alters the interaction capacity of the α2B-AR with spinophilin in the agonist-
bound, active state. Since spinophilin regulates α2B-AR signaling by binding the 3i loop to
recruit RGS proteins and thus resulting in signal attenuation 12, the ADCME mutation, by
reducing this binding, increases the intensity of receptor activation. Accordingly, mutant
α2B-AR shows an increased apparent affinity to epinephrine-stimulated calcium signaling,
in line with the increased potency of epinephrine in stimulating calcium signaling after
spinophilin depletion 13.
Adrenergic stimulation seems to have a dual role on epileptic neuronal firing depending on
the specific neuronal host. Norepinephrine is unique among the monoamine transmitters, in
that it exerts anti-epileptogenic actions in the kindling model, where selective depletion of
norepinephrine in the bundle from the locus coeruleus to the forebrain markedly facilitates
kindling development 37. The anti-epileptogenic actions of norepinephrine are mediated by
the α2 subtype receptors and kindled animal models indicate that impaired activation of α2
receptors may contribute to epileptogenesis 38. This mechanism is possibly mediated by α2
presynaptic autoreceptor responsible for auto-inhibition of norepinephrine release, as
suggested for locus coeruleus neurons where α2-AR activates the inwardly rectifying K+
currents, resulting in decreased spontaneous firing activity39.
On the other hand, the same effect of attenuating neuronal excitation may be exerted on
inhibitory interneuron by postsynaptic α2 receptors. Indeed, dysfunction of GABAergic
signaling plays a critical role in the pathogenesis of epilepsy; in particular, norepinephrine
suppression of the GABA response has been demonstrated to be mediated by α2-AR that
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decreases intracellular cAMP formation through Gi inhibition of adenylyl cyclase 40. Low
cAMP signalling reduces the activity of the hyperpolarization-activated cyclic nucleotide-
gated (HCN) channels and enhances neuronal network firing propensity 41.
Thus, cortical hyperexcitability in ADCME might result from impaired GABAergic
inhibition that controls neuronal excitability 42 and modulates oscillatory activities in the
central motor networks 43. We propose that the ADCME mutation exerts a gain of function
effect by reducing the interaction with spinophilin, and thus increasing receptor activity.
Clinical and electrophysiological features in these families suggest cortical
hyperexcitability, which can be the result of enhanced intrinsic rhythmic activity of cortical
generators 2 or decreased cortical inhibition caused by dysfunction of the cerebello-thalamo-
cortical loop 17. α2-AR stimulation can induce a switch from tonic to burst pattern without
changing the neuronal firing rate 44, which may be at the origin of chronic motor disturbance
of this condition. α2-AR have also been shown to regulate dendrite development in
mammalian cortical neurones 45. Agonists of α2-AR affect length and density of dendritic
spines in cultured cortical neurones and these effects are blocked by α2-AR antagonists.
These changes in the density and length of dendritic spines correlate with increased
expression of spinophilin and a decreased phosphorylation of spinophilin 45. Increased
mutant adrenoceptor function might therefore promote anatomo-pathological changes in the
brain underlying the mild age-dependent progression of the syndrome .
This new association of α2B-AR with a genetic form of epilepsy has remarkable potential
pharmacological relevance by posing the AR agonists and antagonists in a new light and
encouraging the design of subtype specific antagonists to treat at least some forms of the
disease.
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Figure 1. Pedigrees of ADCME families
CM, cortical myoclonus; GTCS, generalized tonic-clonic seizure; CPS, complex partial
seizure. Probands are indicated by arrowheads.
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Figure 2. The ADCME mutation of the α2B-AR
(A) Control and mutant alleles. (B) Partial sequence alignment of AR in multiple species.
The mutant sequence is highlighted.
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Figure 3. Molecular modeling of wild type and mutant α2B-AR
Ribbon diagram of the α2B-AR are rainbow gradient-colored (N terminus, blue, to C
terminus, red). Arrow points to the mutant stretch. TM, transmembrane domain; Cyto,
cytosolic domain.
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Figure 4. Wild type and mutant α2B-AR internalization
Representative images of HeLa cells transfected with wild type (α2B-AR WT) or mutant
(α2B-AR mut) HA-tagged α2B-AR alone or in combination with arrestin3 and stimulated
with epinephrine (epi), where indicated. Scale bar is 30 μm.
De Fusco et al. Page 15
Ann Neurol. Author manuscript; available in PMC 2015 January 02.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 5. The mutant α2B-AR fails to form a stable complex with spinophilin
COS M6 cells co-expressing spinophilin with wild type or mutant α2B-AR are stimulated
with epinephrine and the α2B-AR-spinophilin complex is isolated with an HA antibody. (A)
Representative blot showing spinophilin interaction with the wild type and mutant α2B-AR
after 10 min stimulation of epinephrine. (B) Quantitation of α2B-AR-spinophilin interaction
representing three independent coimmunoisolation experiments. Data are expressed as the
fold change of spinophilin complexed with wild type or mutant α2B-AR over no stimulation
control. Values are given as the mean ± SEM; *p < 0.05, epinephrine stimulated versus
control. (C) Representative blots showing interaction between spinophilin and wild type
(left) or mutant (right) α2B-AR at indicated time points.
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Figure 6. Effect of α2B-AR-spinophilin binding on Ca2+ signaling in Xenopus oocytes
(A) Oocytes expressing wild type or mutant α2B-AR alone (wt α2B-AR and mut α2B-AR) or
with spinophilin (wt α2B-AR +spl and mut α2B-AR +spl, respectively) were stimulated with
increasing concentrations of epinephrine while measuring the Ca2+-activated Cl− current.
The results are shown as means ± s.e.m. of the peak current from at least 6 replicates in 4
independent experiments (wt α2B-AR vs wt α2B-AR +spl, p<0.01; wt α2B-AR +spl vs mut
α2B-AR +spl, p<0.001). (B) A raw data trace is shown. Oocytes injected with the indicated
cRNA was used 96 hrs post injection to measure activation of the Ca2+-activated Cl−
current by the indicated concentrations of epinephrine.
De Fusco et al. Page 17
Ann Neurol. Author manuscript; available in PMC 2015 January 02.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
De Fusco et al. Page 18
Table 1
Clinical features of affected members of family B.
Patient ID/Sex/Age, y Age at onset Mental status Seizure types Brain MRI Anticonvulsants
I:2/F/70 NA Normal GTCS NA No
II:4/M/84 49 Normal GTCS Normal PB
III:2/F/55 28 Borderline GTCS, focal seizures Normal PB, VPA, CNZ
III:5/M/45 27 Normal GTCS, focal seizures Normal VPA, LEV, CNZ
IV:1/F/29 18 Normal No ND No
NA. not available; IQ: intelligence quotient; GTCS: generalized tonic-clonic seizures; PB: Phenobarbital; VPA: valproate; CNZ: clonazepam,
LEV: levetiracetam
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